ישראל - עברית - Ministry of Health

novartis pharma services ag - terbinafine hydrochloride 281.25 mg - tablets - terbinafine - fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum. oral lamisil should only be used to treat extensive, severe ringworm infections ( tinea corporis, tinea cruris and tinea pedis). oral lamisil is not effective against vaginal candidiasis or pityriasis (tinea) versicolor. onychomycoses ( tinea unguium, ringworm of the nails) due to infecton with dermatophyte organisms ( hyphomycetes).

ישראל - עברית - Ministry of Health

novartis pharma services ag - terbinafine hydrochloride 281.25 mg - tablets - terbinafine - fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum. oral lamisil should only be used to treat extensive, severe ringworm infections ( tinea corporis, tinea cruris and tinea pedis). oral lamisil is not effective against vaginal candidiasis or pityriasis (tinea) versicolor. onychomycoses ( tinea unguium, ringworm of the nails) due to infecton with dermatophyte organisms ( hyphomycetes).

ישראל - עברית - Ministry of Health

devries & co. ltd - crotamiton - קרם - crotamiton 10 %w/w - hydrocortisone - hydrocortisone - relief of pruritus and treatment of scabies.

ישראל - עברית - Ministry of Health

novartis pharma services ag - methylergometrine maleate 125 mcg - tablets - methylergometrine - prevention or treatment of uterine haemorrhage.

ישראל - עברית - Ministry of Health

bayer israel ltd - drospirenone; estradiol as hemihydrate - טבליות מצופות פילם - drospirenone 2 mg; estradiol as hemihydrate 1 mg - estradiol - estradiol - angeliq is indicated for hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women more than 1 year post menopause. prevention of postmenopausal osteoporosis in women with an increased risk of future osteoporosis fractures.

ישראל - עברית - Ministry of Health

novartis pharma services ag - tetracosactide hexaacetate 1 mg/ml - suspension for injection - tetracosactide - collagen diseases, neurological diseases, chronic skin disorders.

ישראל - עברית - Ministry of Health

novartis pharma services ag - calcitonin salmon 2200 iu/ml - solution - calcitonin (salmon synthetic) - bone pain associated with osteolysis due to malignancies. paget's disease of bone only in patients who do not respond to alternative treatments or for whom such treatments are not suitable. neurodystrophic disorders.

ישראל - עברית - Ministry of Health

j-c health care ltd - golimumab - תמיסה להזרקה - golimumab 50 mg / 0.5 ml - golimumab - golimumab - rheumatoid arthritis :simponi, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drug (dmard) therapy including mtx has been inadequate.psoriatic arthritis :simponi, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate.ankylosing spondylitis :simponi is indicated for the treatment of adult patients with severe active ankylosing spondylitis who have responded inadequately to conventional therapy.

ישראל - עברית - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to,or have contraindication to or who are intolerant to other systemic therapies including ciclosporin,methotrexate and psoralen plus u.v (puva).

ישראל - עברית - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen plus u.v (puva).